• Lakefront Biotherapeutics swung to a first-half 2026 net profit of €16.6 million from a year-earlier loss.
• Total net revenues fell 87% year over year to €18.59 million.
• Cash, cash equivalents and financial investments totaled €2.24 billion at June 30, following €733.52 million in net acquisition outflows for Ouro Medicines.
• The completed Ouro acquisition added gamgertamig, an autoimmune disease treatment expected to enter registrational studies in 2027.
• Year-end 2026 cash and financial investments are forecast at €1.98 billion–€2.05 billion, including the €50 million share buyback program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.